Curr Gastroenterol Rep. 2007 Mar;9(1):54-9.

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Source

Division of Gastroenterology and Hepatology, Saint Louis University, 3635 Vista at Grand Boulevard, St. Louis, MO 63110, USA. befelera@slu.edu

Abstract

Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that results in progressive fibrosis of intrahepatic and extrahepatic bile ducts. No effective therapy currently exists for this disease. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is the most promising treatment option because of its benign side effect profile and documented benefit in the treatment of other cholestatic liver diseases, including primary biliary cirrhosis. Multiple studies using standard-dosage (8-15 mg/kg/d) and high-dosage (20-30 mg/kg/d) UDCA generally show improvement in liver chemistries in PSC patients, and several show improvement in liver histology. However, the majority of trials using UDCA in PSC are underpowered and fail to show improvements in clinically relevant endpoints, such as delayed progression to cirrhosis, portal hypertension, liver transplantation, development of cholangiocarcinoma, or death.

PMID:: 17335678; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Bile Duct Diseases - MedlinePlus Health Information

Supplemental Content

Related citations

Review [Treatment of cholestatic liver diseases with ursodeoxycholic acid]. [Tidsskr Nor Laegeforen. 1997]
Review [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM, Schrumpf E. Tidsskr Nor Laegeforen. 1997 Sep 30; 117(23):3370-3.
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. [Gastroenterology. 2001]
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. Gastroenterology. 2001 Oct; 121(4):900-7.
Review Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. [Digestion. 2001]
Review Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J, Leuschner U. Digestion. 2001; 64(3):137-50.
Review Primary sclerosing cholangitis. [Can J Gastroenterol. 2000]
Review Primary sclerosing cholangitis.
Stiehl A, Benz C, Sauer P. Can J Gastroenterol. 2000 Apr; 14(4):311-5.
Review The medical management of primary sclerosing cholangitis. [Medscape J Med. 2008]
Review The medical management of primary sclerosing cholangitis.
Michaels A, Levy C. Medscape J Med. 2008 Mar 12; 10(3):61. Epub 2008 Mar 12.

See reviews... See all...

Cited by 2 PubMed Central articles

Current and future therapy for primary sclerosing cholangitis. [Gastroenterol Hepatol (N Y). 2008]
Current and future therapy for primary sclerosing cholangitis.
Mendes F. Gastroenterol Hepatol (N Y). 2008 Apr; 4(4):258-60.
Review Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. [HPB (Oxford). 2011]
Review Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.
Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M. HPB (Oxford). 2011 Feb; 13(2):79-90.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangit...
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Curr Gastroenterol Rep. 2007 Mar ;9(1):54-9.

PubMed
NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cell...
NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.
Breast Cancer Res Treat. 2008 Oct ;111(3):419-27. Epub 2007 Oct 27 .

PubMed
Anticancer effects of phytosterols.
Anticancer effects of phytosterols.
Eur J Clin Nutr. 2009 Jul ;63(7):813-20. Epub 2009 Jun 3 .

PubMed
The token economy for children with intellectual disability and/or autism: a rev...
The token economy for children with intellectual disability and/or autism: a review.
Res Dev Disabil. 2009 Mar-Apr ;30(2):240-8. Epub 2008 May 16 .

PubMed
On superconductivity and superfluidity (what I have and have not managed to do),...
On superconductivity and superfluidity (what I have and have not managed to do), as well as on the 'physical minimum' at the beginning of the 21 st century.
Chemphyschem. 2004 Jul 19 ;5(7):930-45.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: